AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06158412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans Retinoic Acid in combination with the KPD Regimen
Description: Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; >75 years: 20 mg/day.
Study NCT05463757 — intervention group
Intervention type: DRUG
Intervention: Vismodegib
Description: Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
Study NCT05463757 — intervention group
Intervention type: DRUG
Intervention: Sonidegib
Description: Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
Study NCT06070142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP Group
Description: Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study NCT06070142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eTEP Group
Description: Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study NCT05805033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mucointegration
Description: Placement of abutment on a dental implant to study mucointegration
Study NCT05805033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mucointegration
Description: Placement of abutment on a dental implant to study mucointegration
Study NCT04989348 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gonadotrophin releasing hormone antagonist protocol
Description: Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
Study NCT04989348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progestin-primed ovarian stimulation protocol
Description: Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
Study NCT06434571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth cognitive behavioral therapy for insomnia (tCBT-I)
Description: The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention
Study NCT06434571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy for insomnia (wCBT-I)
Description: Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
Study NCT06434571 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
Study NCT05354726 — intervention group
Intervention type: OTHER
Intervention: Assessments parameters
Description: Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
Study NCT04537247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial nephrectomy for complex renal tumor
Description: removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
Study NCT02861183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OVT (Sodium Hyaluronate)
Description: A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
Study NCT02861183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
Study NCT05994781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyDew MD regen cram
Description: No intervention
Study NCT05617820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Vaginal Insert, 4 mcg tablet
Study NCT05617820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imvexxy
Description: Estradiol 4 mcg Vaginal Insert
Study NCT05617820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Vaginal Insert
Study NCT06432621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation
Description: patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
Study NCT06482710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinwheel
Description: The children in the intervention group were given breathing exercises with pinwheels.
Study NCT05717829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified hip capsular incision
Description: modified incision to make re -suturing of the capsule easier with multiple stitches.
Study NCT06222463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
Study NCT06222463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evone
Description: Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
Study NCT05719714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: 10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
Study NCT04765033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized 5% Hypertonic saline
Description: nebulized 0.9% saline
Study NCT04765033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 5% Hypertonic saline
Description: nebulized 0.9% saline
Study NCT05710302 — intervention group
Intervention type: OTHER
Intervention: Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure
Description: Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
Study NCT06459609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplementation
Description: Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
Study NCT05440045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MW3211
Description: 6MW3211 injection, 30mg/kg, Q2W
Study NCT05772949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group intervention
Description: The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study.
Study NCT05772949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wait-list control group intervention
Description: The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids.
Study NCT05378399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy or Truvada
Description: Descovy or Truvada prescribed with digital pills for PrEP
Study NCT05378399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Cap System
Description: Digital pills overencapsulating Descovy or Truvada for PrEP
Study NCT05378399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beiwe
Description: Digital phenotyping app
Study NCT06323824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Drug: Methadone~Possible formulations:~10 and 40 mg tablets
Study NCT06633263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
Study NCT06633263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression
Description: Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
Study NCT05975385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
Study NCT06059716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten detection technology
Description: Portable technology to sense gluten after ingestion
Study NCT06059716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous telemedicine monitoring
Description: Regular follow-up with an expert dietitian
Study NCT05890326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Description: Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
Study NCT05890326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery-based exercise protocol (MIEP)
Description: All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI).
Study NCT05890326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combination Group
Description: Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
Study NCT05606692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1%
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Study NCT06059716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous telemedicine monitoring
Description: Regular follow-up with an expert dietitian
Study NCT05606692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane/Ultane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
Study NCT04131361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
Study NCT04131361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
Study NCT05445115 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mollie device
Description: medical device
Study NCT05445115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mollie device
Description: medical device
Study NCT04441073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: preoperative nebulization of lignocaine
Study NCT04441073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
Study NCT05224596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and blood-based biomarkers analyses
Description: blood-based biomarkers analyses
Study NCT05058144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinkable solution
Description: the volunteer will consume the volume 300 ml of water with
Study NCT05058144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinkable solution
Description: the volunteer will consume the volume 300 ml of water with
Study NCT05222919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bare performance supplement
Description: dietary supplement
Study NCT05222919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04460989 — intervention group
Intervention type: PROCEDURE
Intervention: arthroplasty
Description: total knee replacement
Study NCT04962464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak Human Labs calorie mimetic supplement
Description: Supplement
Study NCT04962464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Diet
Study NCT05641168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesive material
Description: Newly developed adhesive material
Study NCT05641168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard adhesive material
Description: Standard adhesive material
Study NCT06146348 — intervention group
Intervention type: BEHAVIORAL
Intervention: adapted DRAUP strategy bundle
Description: DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
Study NCT05993078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl 2000ml
Description: The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Study NCT05993078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl 200-400ml
Description: The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Study NCT06323824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine (BUP)
Description: Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)
Study NCT04852419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5
Study NCT04793711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiCeram
Description: protective emollient
Study NCT05479968 — intervention group
Intervention type: DEVICE
Intervention: Spectrocor device
Description: This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
Study NCT04559620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal voice
Description: Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days